RVTY

145.2204.20%
PW

Pascale Witz

Independent Member of Supervisory Board

Ms. Pascale Witz, MBA, MSc, is Chairman of Augustine Therapeutics N.V. from April 9, 2025. She serves as Chair, Board of Directors of RTI Surgical Inc. since June 2021. She serves as Advisor at Portal Instruments, Inc and also served as Director since February 2024 until 2025. She has been Member of Supervisory Board at Fresenius Medical Care Management AG since May 20, 2021. Ms. Witz served as Independent Director of Arkuda Therapeutics, Inc. She serves as an Independent Director at WIRB-Copernicus Group, Inc. since November 2020. She serves as Independent Director of Revvity, Inc. (formerly known as PerkinElmer, Inc.) since October 27, 2017. Ms. Witz served as a Director at Tesaro, Inc. since May 10, 2018 until January 22, 2019. She served as a Director of Savencia SA from April 2016 to April 2018. Ms. Witz has served as the Chief Executive Officer and President of PWH Advisors SASU, a consulting services firm for healthcare companies, since founding in November 2016. Before joining Sanofi, Ms. Witz served as President and Chief Executive Officer of GE’s pharmaceutical diagnostics, a 2 billion integrated pharmaceutical business that encompassed research and development through commercialization. She is Chief Executive Officer of PWH ADVISORS Limited Liability Company. She served as Executive Vice President, Global Pharma and Consumer Healthcare divisions at Sanofi S.A. Ms. Witz served as Executive Vice President of Global Diabetes & Cardiovascular at Sanofi S.A. since September 2015 until May 2016 and served as its Executive Vice President of Global Divisions and Strategic Development since July 1, 2013. She has served as Director at Perkin Elmer Incorporated since October 30, 2017. She formerly worked for Becton Dickinson Pharmaceutical Systems from 1991 to 1996. She served as the Chief Executive Officer of Medical Diagnostics Business and President of Medical Diagnostics Business (MDx) at GE Healthcare Ltd. from March 2009 to June 2013. She joined GE in 1996, as a Global Product Manager for Interventional Radiology. She joined GE Healthcare (GEHC) in 1996. Prior to joining MDx in April 2009, she served successfully in a number of senior management roles, including leading GEHC's Functional Imaging (Nuclear Medicine and PET) business in EMEA, the CT (Computed Tomography) business in EMEA and the Interventional Radiology and Cardiology business globally. She held a number of strategic and global leadership roles at GE Healthcare. She led GE Healthcare's Interventional global business. She joined Sanofi in July 2013 as Executive Vice President, pharma and CHC divisions. Ms. Witz also served on the boards of Directors of Fresenius Medical Care AG & Co. KGaA. She serves as Director at CellCarta Biosciences, a private biopharma services company, WGC Clinical Services, a private biopharma services company and Value Demonstration Group Holdings. Ms. Witz Headed up a number of businesses. She was Vice President of Information Technology and Vice President of Six Sigma and Quality from 2000 to 2001, General Manager of Nuclear Medicine & PET from 2002 to 2004, Vice President of Sales & Marketing Services from 2005 to 2006, General Manager of Computed Tomography from 2006 to 2007, Vice President & General Manager for the Global Interventional Business for France and US from 2008 to 2009. She worked in a molecular biology research laboratory and spent few years in the pharmaceutical industry. She has more than two decades of global healthcare management experience. Ms. Witz had been Independent Director of Regulus Therapeutics Inc. since June 1, 2017 until June 25, 2025. She served as a Director of Nihon Medi-Physics Co. Ltd until June 30, 2013. She had been Independent Director of Horizon Therapeutics Public Limited Company (formerly known as Horizon Pharma plc) since August 3, 2017 until October 06, 2023. She serves as an Independent Member of Supervisory Board at Fresenius Medical Care AG (formerly Fresenius Medical Care AG & Co. KGAA) since May 12, 2016. She was a Director of WCG Clinical, Inc. She serves as a Member of the Board of the French American Foundation France. She is an active leader in the GE Women's Network and serves on its executive board. Ms. Witz received her Master of Science in Biochemistry from the Institut National des Sciences Appliques (INSA) Lyon, France and an MBA in Economics and Marketing from INSEAD, Fontainebleau, France. She was also a Ph.D. student in Molecular Biology at the Centre National de la Recherche Scientifique, Strasbourg, France.

Positions